roche holding ag - RHHBY

RHHBY

Close Chg Chg %
35.13 0.16 0.46%

Pre-Market

35.29

+0.16 (0.46%)

Volume: 1.46M

Last Updated:

Nov 21, 2024, 4:00 PM EDT

Company Overview: roche holding ag - RHHBY

RHHBY Key Data

Open

$35.40

Day Range

35.23 - 35.50

52 Week Range

29.20 - 42.43

Market Cap

$193.95B

Shares Outstanding

5.52B

Public Float

5.52B

Beta

0.44

Rev. Per Employee

N/A

P/E Ratio

18.73

EPS

N/A

Yield

241.13%

Dividend

$0.85

EX-DIVIDEND DATE

Mar 14, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

1.17M

 

RHHBY Performance

1 Week
 
-1.53%
 
1 Month
 
-13.01%
 
3 Months
 
-15.39%
 
1 Year
 
5.24%
 
5 Years
 
-7.30%
 

RHHBY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 20
Full Ratings ➔

About roche holding ag - RHHBY

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

RHHBY At a Glance

Roche Holding AG
Grenzacherstrasse 124
Basel, Basel-Stadt (Basle Town) 4058
Phone 41-61-688-11-11 Revenue 65.34B
Industry Pharmaceuticals: Major Net Income 12.79B
Sector Health Technology Employees 103,605
Fiscal Year-end 12 / 2024
View SEC Filings

RHHBY Valuation

P/E Current 18.731
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 18.10
Price to Sales Ratio 3.567
Price to Book Ratio 6.634
Price to Cash Flow Ratio 13.517
Enterprise Value to EBITDA 11.869
Enterprise Value to Sales 4.007
Total Debt to Enterprise Value 0.14

RHHBY Efficiency

Revenue/Employee 630,644.078
Income Per Employee 123,495.225
Receivables Turnover 4.237
Total Asset Turnover 0.644

RHHBY Liquidity

Current Ratio 1.347
Quick Ratio 1.035
Cash Ratio 0.423

RHHBY Profitability

Gross Margin 73.06
Operating Margin 27.844
Pretax Margin 24.033
Net Margin 19.582
Return on Assets 12.62
Return on Equity 39.317
Return on Total Capital 17.919
Return on Invested Capital 21.295

RHHBY Capital Structure

Total Debt to Total Equity 105.004
Total Debt to Total Capital 51.221
Total Debt to Total Assets 34.025
Long-Term Debt to Equity 89.002
Long-Term Debt to Total Capital 43.415
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Roche Holding Ag - RHHBY

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
62.14B 68.69B 66.26B 65.34B
Sales Growth
+0.46% +10.55% -3.54% -1.39%
Cost of Goods Sold (COGS) incl D&A
17.42B 21.55B 19.72B 17.60B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.86B 4.86B 4.00B 3.87B
Depreciation
3.00B 3.16B 3.02B 3.07B
Amortization of Intangibles
1.86B 1.70B 982.13M 796.75M
COGS Growth
-1.96% +23.69% -8.48% -10.76%
Gross Income
44.71B 47.14B 46.54B 47.74B
Gross Income Growth
+1.44% +5.42% -1.28% +2.58%
Gross Profit Margin
+71.96% +68.63% +70.23% +73.06%
2020 2021 2022 2023 5-year trend
SG&A Expense
25.54B 27.98B 27.30B 29.31B
Research & Development
12.95B 14.99B 14.71B 14.72B
Other SG&A
12.60B 12.98B 12.59B 14.59B
SGA Growth
+2.88% +9.52% -2.40% +7.35%
Other Operating Expense
282.33M 260.32M 201.03M 233.68M
Unusual Expense
678.66M 3.03B 4.59B 3.54B
EBIT after Unusual Expense
18.21B 15.88B 14.44B 14.65B
Non Operating Income/Expense
1.40B 3.53B 3.33B 1.97B
Non-Operating Interest Income
- - - 17.05M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
466.65M 372.98M 636.61M 921.38M
Interest Expense Growth
-25.20% -20.07% +70.68% +44.73%
Gross Interest Expense
466.65M 372.98M 636.61M 921.38M
Interest Capitalized
- - - -
-
Pretax Income
19.14B 19.03B 17.14B 15.70B
Pretax Income Growth
+14.39% -0.57% -9.95% -8.38%
Pretax Margin
+30.80% +27.71% +25.87% +24.03%
Income Tax
3.09B 2.69B 2.93B 1.92B
Income Tax - Current - Domestic
3.74B 2.86B 4.66B 3.15B
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(649.89M) (170.63M) (1.74B) (1.24B)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
16.05B 16.34B 14.17B 13.75B
Minority Interest Expense
823.55M 1.10B 1.16B 956.99M
Net Income
15.23B 15.24B 13.01B 12.79B
Net Income Growth
+12.14% +0.04% -14.64% -1.62%
Net Margin Growth
+24.51% +22.18% +19.63% +19.58%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
15.23B 15.24B 13.01B 12.79B
Preferred Dividends
- - - -
-
Net Income Available to Common
15.23B 15.24B 13.01B 12.79B
EPS (Basic)
2.2266 2.2406 2.0321 2.0017
EPS (Basic) Growth
+12.27% +0.63% -9.31% -1.50%
Basic Shares Outstanding
6.84B 6.80B 6.40B 6.39B
EPS (Diluted)
2.2007 2.2144 2.0321 1.9892
EPS (Diluted) Growth
+12.02% +0.62% -8.23% -2.11%
Diluted Shares Outstanding
6.92B 6.88B 6.40B 6.43B
EBITDA
23.75B 23.77B 23.03B 22.06B
EBITDA Growth
+1.69% +0.07% -3.09% -4.23%
EBITDA Margin
+38.23% +34.60% +34.76% +33.76%

Roche Holding Ag in the News